Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...

The Bristol Myers Squibb subsidiary RayzeBio has opened a new 77,000-square-foot facility in Indianapolis, Indiana.

Bristol Myers Squibb is preparing to ship a new and possibly life-changing cancer treatment to patients across the world. The ...

RayzeBio is also building the infrastructure for producing its radiopharmaceuticals. The company has budgeted about $40 million for completing construction of a manufacturing facility in Indianapolis.

RayzeBio Inc., a San Diego-based company that is building a large factory on the northwest side of Indianapolis to make radioisotopes for cancer treatment, has agreed to be acquired by ...

Under this deal, Philochem will grant RayzeBio exclusive worldwide rights to develop, manufacture, and market OncoACP3, a diagnostic agent aimed at prostate cancer.

After leading his previous company through a back-to-back IPO and M&A deal, the former chief executive of RayzeBio has raised $370 million to develop ...

Radiopharmaceutical company RayzeBio, a wholly owned subsidiary of Bristol Myers Squibb, will license a therapeutic and diagnostic asset for prostate cancer from Philochem. The deal is worth $350 ...

RayzeBio also hopes to use some of the IPO haul to finish construction of a GMP manufacturing facility in Indianapolis, the company said in the filing.

Following a $45 million renovation, RayzeBio plans to use the plant to make Actinium 225, a radioisotope used for targeted therapy for cancer.

Besides just the RPT technology, BMY will also be gaining a manufacturing facility. RayzeBio is completing construction of a state-of-the-art in-house manufacturing facility in Indianapolis. GMP drug ...

Bristol Myers Squibb's $4.1 billion bid for RayzeBio was enough to beat out two other companies that also put down offers.